Novo Nordisk Management
Management criteria checks 3/4
Novo Nordisk's CEO is Lars Jorgensen, appointed in Jan 2017, has a tenure of 7.92 years. directly owns 0.002% of the company’s shares, worth $8.07M. The average tenure of the management team and the board of directors is 3.8 years and 6.8 years respectively.
Key information
Lars Jorgensen
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 7.9yrs |
CEO ownership | 0.002% |
Management average tenure | 3.8yrs |
Board average tenure | 6.8yrs |
Recent management updates
No updates
Recent updates
Novo Nordisk Stock: A Rare Buying Opportunity
Dec 20Novo Nordisk: Just The Right Price (Rating Upgrade)
Dec 11Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Nov 25Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Nov 06Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Oct 21Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Sep 18Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now
Sep 10Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | DKK 95b |
Jun 30 2024 | n/a | n/a | DKK 90b |
Mar 31 2024 | n/a | n/a | DKK 89b |
Dec 31 2023 | n/a | n/a | DKK 84b |
Sep 30 2023 | n/a | n/a | DKK 75b |
Jun 30 2023 | n/a | n/a | DKK 67b |
Mar 31 2023 | n/a | n/a | DKK 61b |
Dec 31 2022 | DKK 60m | DKK 17m | DKK 56b |
Sep 30 2022 | n/a | n/a | DKK 53b |
Jun 30 2022 | n/a | n/a | DKK 51b |
Mar 31 2022 | n/a | n/a | DKK 49b |
Dec 31 2021 | DKK 58m | DKK 17m | DKK 48b |
Sep 30 2021 | n/a | n/a | DKK 46b |
Jun 30 2021 | n/a | n/a | DKK 44b |
Mar 31 2021 | n/a | n/a | DKK 43b |
Dec 31 2020 | DKK 57m | DKK 14m | DKK 42b |
Sep 30 2020 | n/a | n/a | DKK 42b |
Jun 30 2020 | n/a | n/a | DKK 41b |
Mar 31 2020 | n/a | n/a | DKK 40b |
Dec 31 2019 | DKK 55m | DKK 14m | DKK 39b |
Sep 30 2019 | n/a | n/a | DKK 39b |
Jun 30 2019 | n/a | n/a | DKK 38b |
Mar 31 2019 | n/a | n/a | DKK 38b |
Dec 31 2018 | DKK 41m | DKK 11m | DKK 39b |
Sep 30 2018 | n/a | n/a | DKK 38b |
Jun 30 2018 | n/a | n/a | DKK 39b |
Mar 31 2018 | n/a | n/a | DKK 39b |
Dec 31 2017 | DKK 32m | DKK 9m | DKK 38b |
Compensation vs Market: Insufficient data to establish whether Lars's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.
CEO
Lars Jorgensen (58 yo)
7.9yrs
Tenure
DKK 60,100,000
Compensation
Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 7.9yrs | DKK 60.10m | 0.0021% $ 8.1m | |
Executive VP | 6.8yrs | DKK 21.50m | 0.000010% $ 38.4k | |
Executive VP of Product Supply | no data | DKK 22.00m | 0.000060% $ 230.6k | |
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board | no data | DKK 21.30m | no data | |
Executive VP of Development & Member of the Management Board | 3.9yrs | DKK 20.90m | no data | |
EVP of Research & Early Development | 3.8yrs | DKK 20.90m | no data | |
Executive VP of International Operations & Member of the Management Board | no data | no data | 0.0011% $ 4.4m | |
Executive VP of North America Operations & Member of Management Board | no data | no data | no data | |
Executive VP | no data | no data | no data | |
Executive VP of Global People & Organisation and Member of Management Board | 1.8yrs | no data | no data | |
Executive VP of Corporate Development & Member of Management Board | 1.8yrs | no data | no data | |
Head of Investor Relations | no data | no data | no data |
3.8yrs
Average Tenure
54yo
Average Age
Experienced Management: NVO's management team is considered experienced (3.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Director | 9.8yrs | DKK 1.80m | no data | |
Independent Chairman of the Board | 7.8yrs | DKK 3.10m | no data | |
Vice Chairman of the Board | 3.8yrs | DKK 2.00m | no data | |
Independent Director | 5.8yrs | DKK 2.00m | no data | |
Independent Director | 6.8yrs | DKK 1.70m | no data | |
Independent Director | 6.8yrs | DKK 1.40m | no data | |
Non-Independent Director | 7.8yrs | DKK 1.20m | no data | |
Independent Director | 2.8yrs | DKK 1.30m | no data | |
Employee Representative Director | 2.8yrs | DKK 800.00k | 0% $ 0 | |
Employee Non-Independent Representative Director | 6.8yrs | DKK 1.20m | no data | |
Employee Representative Non-Independent Director | 6.9yrs | DKK 1.00m | no data | |
Employee Representative Director | 2.8yrs | DKK 800.00k | no data |
6.8yrs
Average Tenure
58.5yo
Average Age
Experienced Board: NVO's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 11:36 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Nordisk A/S is covered by 71 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | ABG Sundal Collier |
Kamla Singh | AlphaValue |
Gerhard Schwarz | Baader Helvea Equity Research |